Compare Citius Pharmaceuticals Inc (CTXR) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs MINISO Group Holding Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while MINISO Group Holding Ltd trades at $9.2 (market cap $2.65B). The key difference: MINISO Group Holding Ltd is far larger — about 194.6× Citius Pharmaceuticals Inc's market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and MINISO Group Holding Ltd for 24 Days on average.
| CTXR | MNSO | |
|---|---|---|
Market Cap | $13.62M | $2.65B |
Volume | 132,438 | 747,763 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $22.75 |
52-Week Low | $0.48 | $8.60 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.79M | $3.52B |
Dividend Yield | — | 7.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing estimates in three of the last four quarters but beating in Q1 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 5.35%. Analyst sentiment is mixed with a 60% buy rating, while recent news highlights CFO share purchases and a 52-week low.
The outlook for MNSO hinges on improving earnings consistency and margin stabilization. Investment opportunities include attractive valuation multiples like a P/E of 14.55 and P/S of 0.78, but risks involve volatile earnings, overseas margin pressures, and competitive retail dynamics. The stock's recent decline to near 52-week lows may present a value entry if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
